The U.S. Food and Drug Administration has approved Moderna's mFLUSIVA, marking the first time a messenger RNA flu vaccine has received regulatory authorization. The agency approved the shot for people aged 50 and older on August 8, 2026. Juan Scaliter reported that the decision grants traditional approval for adults aged 50 to 64 and accelerated approval for individuals aged 65 and older.
An FDA document noted that unlike conventional manufacturing, the mRNA platform allows streamlined development and rapid responses to emerging mutations in viruses. For people aged 65 and older, the agency is requiring a post-approval study to confirm the clinical benefit of the vaccine.
Influenza viruses change every season, turning vaccine preparation into a race against time. The virus circulating during winter is not necessarily identical to the one behind the previous epidemic, and the pathogen continues mutating while scientists prepare immunization shots.
Traditional influenza vaccine production
Until now, seasonal flu shots relied on other technologies, with many produced by growing viruses in chicken eggs. While egg-based manufacturing has functioned for decades, it requires significant time. Every season, scientists must predict which influenza variants will circulate during the following months.
For the 2026-2027 U.S. season, the FDA selected influenza A H1N1, H3N2, and a Victoria lineage influenza B virus based on epidemiological surveillance data and antigenic characteristics of circulating viruses. Because decisions occur far in advance, viruses can mutate before the season begins, leaving vaccines facing a slightly different target than expected.
Egg-based manufacturing also carries another drawback when viruses multiply inside eggs. This multiplication can produce egg adaptations that alter characteristics of the viral surface protein recognized by the human immune system. FDA documentation indicates this adaptation process can cause conventional shots to fit circulating viruses less effectively.
How mRNA flu technology works
Messenger RNA technology uses a different strategy than traditional vaccines, which contain inactivated viruses, viral fragments, or factory-produced proteins. Messenger RNA is a molecule cells use as a temporary message to manufacture proteins. The vaccine introduces instructions into cells to produce a target protein.
In mFLUSIVA, those instructions correspond to hemagglutinin, one of the main surface proteins on the influenza virus. Cells produce the protein temporarily, prompting the immune system to identify it as foreign and build a defensive response.
The vaccine does not require introducing a replicating virus or growing large amounts of virus in eggs. This approach opens the possibility of modifying instructions rapidly if influenza variants change, which FDA documentation highlights as a key potential advantage over egg-based production.
Clinical trial findings and effectiveness
The primary trial supporting approval involved more than 40,000 adults aged 50 and older. In efficacy testing, mFLUSIVA reduced confirmed influenza cases by 26.6 percent more than a standard-dose conventional flu vaccine.
FDA documentation emphasizes that the 26.6 percent figure represents a relative difference compared to the standard-dose comparator, rather than an absolute protection rate for vaccinated individuals. For adults aged 65 and older, accelerated approval relied on immunogenicity data showing favorable antibody responses compared to a high-dose flu vaccine.
The FDA required a post-marketing study for older adults because an antibody response does not automatically prove that a vaccine prevents more real-world disease cases. The true potential advantage of mFLUSIVA lies in the flexibility of the platform rather than superior protection from this single shot.
Global authorization and existing flu shots
Flu viruses evolve constantly and their proteins change, sometimes causing poor matches between selected vaccine strains and circulating viruses. FDA officials identified manufacturing that allows rapid reformulation as an unaddressed need, particularly during antigenic drift and major viral shifts.
During the COVID-19 pandemic, mRNA platforms demonstrated that scientists could move from a genetic sequence to a vaccine in an extraordinarily short time. The pending question was whether that same technology could succeed against a rapidly changing virus like influenza.
U.S. approval does not authorize mFLUSIVA in Europe, as European regulatory processes operate independently, and the FDA decision does not imply availability in Spain. Traditional flu shots remain useful prevention tools alongside cellular, recombinant, adjuvanted, and high-dose vaccines currently recognized by the FDA.
The FDA approval officially brings mRNA technology into the arsenal against seasonal flu. Beyond serving as a new option for eligible adults, mFLUSIVA acts as a large-scale test of whether updating genetic instructions will allow medicine to keep pace when viruses mutate.
